Role of Long-Term Nucleoside-Analogue Therapy in Lipodystrophy and Metabolic Disorders in Human Immunodeficiency Virus--Infected Patients
Open Access
- 1 March 2002
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (5) , 649-657
- https://doi.org/10.1086/338811
Abstract
The role of nucleoside analogues (NAs) in lipodystrophy (LD) syndrome in human immunodeficiency virus (HIV)—infected patients remains controversial.Keywords
This publication has 28 references indexed in Scilit:
- Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999Clinical Infectious Diseases, 2000
- Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infectionAIDS, 2000
- Fat distribution and metabolic changes in patients with HIV infectionAIDS, 1999
- A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapyAIDS, 1999
- The ALBI Trial: A Randomized Controlled Trial Comparing Stavudine Plus Didanosine with Zidovudine Plus Lamivudine and a Regimen Alternating Both Combinations in Previously Untreated Patients Infected with Human Immunodeficiency VirusThe Journal of Infectious Diseases, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapyAIDS, 1999
- Pseudo‐Cushing's Syndrome in Human Immunodeficiency Virus– Infected PatientsClinical Infectious Diseases, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998